Gilead Sciences, Inc.

NASDAQ:GILD   3:59:59 PM EDT
59.97
-0.82 (-1.35%)
4:19:00 PM EDT: $59.91 -0.06 (-0.10%)
Products, Strategic Combinations, Regulatory

Jyseleca® (Filgotinib) Approved In Japan For Rheumatoid Arthritis

Published: 09/25/2020 06:15 GMT
Gilead Sciences Inc (GILD) - Jyseleca® (filgotinib) Approved in Japan for Rheumatoid Arthritis.
Gilead Sciences - Gilead Japan Will Hold Marketing Authorization of Jyseleca in Japan and Will Be Responsible for Product Supply of Jyseleca in Japan.
Eisai Will Be Responsible for Product Distribution of Jyseleca in Japan in Ra.
Co and Eisai Will Jointly Commercialize Medicine to Make It Available to Physicians and Patients Across Japan.